Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G/A for Definium Therapeutics, Inc. Common Shares.
- Disclosed ownership: 5.5%.
- Date of event: 31 Dec 2025.
Deep Track Capital, LP - 31 Dec 2025 SCHEDULE 13G/A Report for Definium Therapeutics, Inc. Common Shares
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Shares outstanding
- 102,464,621 shares
- Disclosed Ownership
- 5,676,540 shares
- Ownership
- 5.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 08:42:37 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 5.5% ownership in Definium Therapeutics, Inc. Common Shares on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2026, 08:42.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 5.5% | 5,676,540 | 0 | 5,676,540 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 5.5% | 5,676,540 | 0 | 5,676,540 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 5.5% | 5,676,540 | 0 | 5,676,540 | /s/ David Kroin | David Kroin |